References
- Langreth R, Waldholz M. New era of personalized medicine. Oncologist4, 426–427 (1999).
- Jørgensen JT. From blockbuster medicine to personalized medicine. Personalized Medicine5(1), 55–63 (2008).
- Morgan LR, Schein PS, Woolley PV et al. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat. Rep.60, 1437–1443 (2008).
- Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat.52, 65–77 (1998).
- Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
- Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol.17, 1983–1987 (1999).
- Fadel H, Temesgen Z. Maraviroc. Drugs Today43, 749–758 (2007).
- Whitcomb JM, Huang W, Frasen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother.51, 5666–5575 (2007).
- Jørgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies – a rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist12, 397–405 (2007).
- Nielsen KV, Ejlertsen B, Møller S et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol.47, 725–734 (2008).
- Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol. Med.7, 201–204 (2001).
- Frye RF. Probing the world of cytochrome p450 enzymes. Mol. Interv.4, 157–162 (2005).
- Wolf AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol.25, 118–145 (2007).
- Hu SX, Foster T, Kieffaber A. Pharmacogenomics and personalized medicine: mapping of future value creation. BioTechniques39, 1–6 (2005).
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov.6, 287–293 (2007).
- Osler W. The Principles and Practice of Medicine, 1st Edition. D Appleton and Company, NY, USA (1892).
- Woodcock J. The prospects for ‘personalized medicine’ in drug development and drug therapy. Clin.Pharmacol. Ther.81, 164–169 (2007).
- Ferrara J. Personalized medicine: challenging pharmaceutical and diagnostic company business models. Mcgill J. Med.10, 59–61 (2007).
- Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res.10, 6759–6763 (2004).
- Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist10, 104–111 (2007).
- Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer Res.11, 7872–7878 (2005).
- Garrison LP, Austin MJF. Linking pharmacogenetic-based diagnostics and pharmaceuticals for personalized medicine: scientific and economic challenges. Health Affairs25, 1281–1290 (2006).
Websites
- Medical News Today. Four studies affirm significance of monogram’s Trofile™ HIV Co-Receptor Tropism Assay. www.medicalnewstoday.com/articles/63005.php Accessed March 2008.
- New device approval. Dako TOP2A FISH pharmDx™ Kit - P050045. March 28, 2008. www.fda.gov/cdrh/mda/docs/P050045.html Accessed July 2008.
- US FDA drug-diagnostic codevelopment concept paper. (Draft.) April 2005. www.fda.gov/cder/genomics/pharmacoconceptfn.pdf Accessed April 2008.
- The CYP450 Gene Family & Drug Metabolism. Roche Diagnostics. www.roche.com/final_cyp_gene_family.pdf Accessed July 2008.
- Personalized Medicine Coalition (PMC). www.personalizedmedicinecoalition.org/index.php Accessed August 2008.
- Innovation or stagnation: challenges and opportunity on the critical path to new medical products. FDA, March 2004) www.fda.gov/oc/initiatives/criticalpath/whitepaper.html Accessed April 2008.
- Little S. Personalized Medicine – what’s in it for big pharma? Drug Discovery World. www.ddw-online.com/data/pdfs/2005personalised%20medicine.pdf Accessed May 2008.
- Targeted therapies to conquer cancer market by 2015. Pharmaceutical Executive Europe, October 1, 2006. www.pharmexeceurope.com/europharmexec/issue/issueDetail.jsp?id=10446 Accessed May 2008.